Nagoya University logo

Nagoya University
Graduate School of Medicine

Cancer Immune Therapy
Research Center



    1. Morimoto D., Matsumura S., Bustos-Villalobos I., Sibal P.A., Ichinose T., Naoe Y., Eissa I.R., Abdelmoneim M., Mukoyama N., Miyajima N., Tanaka M., Kodera Y., Kasuya H. C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells. Cells 2021. 10, doi: 10.3390/cells10061502.
    2. Miyajima N., Ragab Eissa I., Abdelmoneim M., Naoe Y., Ichinose T., Matsumura S., Bustos-Villalobos I., Mukoyama N., Morimoto D., Shibata M., Takeuchi D., Tsunoda N., Kikumori T., Tanaka M., Kodera Y., Kasuya H. S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model. Nagoya J. Med. Sci. 2021. 83, 683-696.
    3. Eissa I.R., Mukoyama N., Abdelmoneim, M., Naoe, Y., Matsumura S., Bustos-Villalobos I., Ichinose T., Miyajima N., Morimoto D., Tanaka M., Fujimoto, Y., Kodera Y., Kasuya H. Oncolytic herpes simplex virus HF10 (canerpaturev, C-REV) promotes accumulation of CD8+PD-1- tumor-infiltrating T cells in PD-L1 enriched tumor microenvironment. Int. J. Cancer. 2021 March; doi: 10.1002/ijc.33550.
    4. Zhiwen Wu, Toru Ichinose, Yoshinori Naoe, Shigeru Matsumura, Itzel Bustos-Villalobos, Ibrahim Ragab Eissa, Suguru Yamada, Noriyuki Miyajima, Daishi Morimoto, Nobuaki Mukoyama, Yoko Nishikawa, Yusuke Koide, Yasuhiro Kodera, Maki Tanaka, Hideki Kasuya.Combination of Cetuxmab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth.Molecular Therapy-Oncolytics.2019 May;13:107-115.
    5. Ibrahim Ragab Eissa,Itzel Bustos-Villalobos,Toru Ichinose,Shigeru Matsumura,Yoshinori Naoe,Noriyuki Miyajima,Daishi Morimoto,Nobuaki Mukoyama,Wu Zhiwen,Maki Tanaka,Hitoki Hasegawa,Seiji Sumigama,Branko Aleksic,Yasuhiro kodera,Hideki Kasuya.The Current Status and Future Prospects of Oncolytic Viruses Clinical Trials against Melanoma,Glioma,Pancreatic and Breast cancers.Cancers.2018 Sep;10(10).
    6. Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama N, Tanaka M, Kodera Y, Goto H. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer.2018 May;18(1):596.
    7. Ibrahim Ragab Eissa, Yoshinori Naoe, Itzel Bustos-Villalobos, Toru Ichinose, Maki Tanaka, Wu Zhiwen, Nobuaki Mukoyama, Taishi Morimoto, Noriyuki Miyajima, Hitoki Hasegawa, Seiji Sumigama, Branko Aleksic, Yasuhiro Kodera and Hideki Kasuya. Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials. Front. Oncol.2017 July;volumn 7, article 149
    8. Yoshihiro Hotta, Hideki Kasuya, Itzel Bustos, Yoshinori Naoe, Toru Ichinose, Maki Tanaka, Yasuhiro Kodera. Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. Oncolytic Virotherapy. 2017 March;6:31-38.
    9. Tan G, Kasuya H, Sahin TT, Yamamura K, Wu Z, Koide Y, Hotta Y, Shikano T, Yamada S, Kanzaki A, Fujii T, Sugimoto H, Nomoto S, Nishikawa Y, Tanaka M, Tsurumaru N, Kuwahara T, Fukuda S, Ichinose T, Kikumori T, Takeda S, Nakao A, Kodera Y. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft. Int J Cancer. 2015 Apr 1;136(7):1718-30.
    10. Kasuya H, Kodera Y, Nakao A, Yamamura K, Gewen T, Zhiwen W, Hotta Y, Yamada S, Fujii T, Fukuda S, Tsurumaru N, Kuwahara T, Kikumori T, Koide Y, Fujimoto Y, Nakashima T, Hirooka Y, Shiku H, Tanaka M, Takesako K, Kondo T, Aleksic B, Kawashima H, Goto H, Nishiyama Y. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer. Hepatogastroenterology. 2014 May;61(131):599-605.
    11. Yamamura K, Kasuya H, Sahin TT, Tan G, Hotta Y, Tsurumaru N, Fukuda S, Kanda M, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Tanaka M, Kodera Y. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Ann Surg Oncol. 2014 Feb;21(2):691-8.
    12. Kanzaki A, Kasuya H, Yamamura K, Sahin TT, Nomura N, Shikano T, Shirota T, Tan G, Fukuda S, Misawa M, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y, Nakao A. Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes. Cancer Gene Ther. 2012 Apr;19(4):292-8. doi: 10.1038/cgt.2011.91.
    13. Sahin TT, Kasuya H, Nomura N, Shikano T, Yamamura K, Gewen T, Kanzaki A, Fujii T, Sugae T, Imai T, Nomoto S, Takeda S, Sugimoto H, Kikumori T, Kodera Y, Nishiyama Y, Nakao A. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer. Cancer Gene Ther. 2012 Apr;19(4):229-37.
    14. Deguchi T, Shikano T, Kasuya H, Nawa A, Fujiwara S, Takeda S, Gewen T, Sahin TT, Yamada S, Kanzaki A, Yamamura K, Fujii T, Sugimoto H, Nomoto S, Fukuda S, Nishikawa Y, Kodera Y, Nakao A. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers. Hepatogastroenterology. 2012 Sep;59(118):1844-50.
    15. Shirota T, Kasuya H, Kodera Y, Nishikawa Y, Shikano T, Sahin TT, Gewen T, Yamamura K, Fukuda S, Kanzaki A, Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Nakao A. Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer. Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1482-9.
    16. Sahin TT, Fujii T, Kanda M, Nagai S, Kodera Y, Kanzaki A, Yamamura K, Sugimoto H, Kasuya H, Nomoto S, Takeda S, Morita S, Nakao A. Prognostic implications of lymph node metastases in carcinoma of the body and tail of the pancreas. Pancreas. 2011 Oct;40(7):1029-33.
    17. Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, Shirota T, Yamada S, Fujii T, Sugimoto H, Shikano T, Nomoto S, Takeda S, Kodera Y, Nishiyama Y. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther. 2011 Mar;18(3):167-75.
    18. Shikano T, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, Nishikawa Y, Shirota T, Yamada S, Fujii T, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, Nakao A. High therapeutic potential for systemic delivery of a liposome-conjugated herpes simplex virus. Curr Cancer Drug Targets. 2011 Jan;11(1):111-22.
    19. Nomura N, Kasuya H, Watanabe I, Shikano T, Shirota T, Misawa M, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, Nakao A. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Cancer Chemother Pharmacol. 2009 Jan;63(2):321-30.
    20. Watanabe I, Kasuya H, Nomura N, Shikano T, Shirota T, Kanazumi N, Takeda S, Nomoto S, Sugimoto H, Nakao A. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol. 2008 Apr;61(5):875-82.
    21. Kasuya H, Nishiyama Y, Nomoto S, Goshima F, Takeda S, Watanabe I, Nomura N, Shikano T, Fujii T, Kanazumi N, Nakao A. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther. 2007 Jun;14(6):533-42.
    22. Kasuya H, Takeda S, Shimoyama S, Shikano T, Nomura N, Kanazumi N, Nomoto S, Sugimoto H, Nakao A. Oncolytic virus therapy--foreword. Curr Cancer Drug Targets. 2007 Mar;7(2):123-5.
    23. Kasuya H, Nakao A. [Clinical application of replication competent mutant HSV in cancer therapy]. Nihon Rinsho. 2006 Mar;64 Suppl 3:335-9. Review. ]
    24. Kasuya H, Takeda S, Nomoto S, Nakao A. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther. 2005 Sep;12(9):725-36. Review.
    25. Kasuya H, Nomoto S, Nakao A. The potential of gene therapy in the treatment of pancreatic cancer. Drugs Today (Barc). 2002 Jul;38(7):457-64. Review. PubMed
    26. Kasuya H, Nomoto S, Kimata H, Harada A, Takeda S, Hayashi S, Nakao A. Gene therapy for pancreatic cancer. Hepatogastroenterology. 2001 Jul-Aug;48(40):957-61. Review.
    27. Kasuya H, Mizuno M, Yoshida J, Nishiyama Y, Nomoto S, Nakao A. Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy. J Surg Oncol. 2000 Jul;74(3):214-8.
    28. Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol. 1999 Nov;72(3):136-41.